THE European Medicines Agency (EMA) announced on Tuesday (20/7) that it has started its real-time evaluation vaccine against coronavirus prepared by the French pharmaceutical company Sanofi and the British GlaxoSmithKline, the fifth vaccine currently under evaluation by the European authorities.
The decision to start the “rolling evaluation” of the vaccine Vidprevtyn relied on preliminary results from laboratory studies and from the first evidence of clinical trials in adults, underlined EMA.
According to the RES EIA, the worldwide final clinical trials of this candidate vaccine against SARS-CoV-2, based on its technology recombinant protein, started him May.
Sanofi and GSK hope to receive marketing authorization of their vaccine until the end 2021, after preliminary results showed that the vaccine produces a strong immune response, according to the same source.
The French pharmaceutical company has announced that other rolling evaluations of its vaccine will also be launched in Britain, τον Canada and Singapore, as well as with him World Health Organization.
Vidprevtyn uses the same technology as Sanofi vaccines against seasonal flu.
It will be combined with one adjuvant medicine, a substance that acts as a vaccine booster, produced by GSK.
It is recalled that the other candidate vaccines against Covid-19 in the rolling EMA evaluation are those of CureVac, Novavax, Sinovac and Sputnik-V.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
